News Archive

Adrian Hernandez is pictured holding his lifetime achievement award from the QCOR council which was presented to him at AHA2024.

Hernandez Honored with QCOR Outstanding Lifetime Achievement Award

The American Heart Association's (AHA) Council on Quality of Care and Outcomes Research (QCOR) Council bestowed the Outstanding Lifetime Achievement Award on Adrian Hernandez, MD, MHS, the executive director of the Duke Clinical Research Institute (DCRI) and vice dean at the Duke University School of Medicine, during the AHA Scientific Sessions on November 16. The award is presented annually at the AHA Scientific Sessions to a QCOR Council member for their significant long-term contributions to outcomes research and the improvement of cardiovascular care.
Two people sit in a meeting listening attentively to a third person whose back is turned to the viewer.

Accelerating Evidence Generation: Addressing Critical Challenges and Charting a Path Forward

Healthcare leaders have united to tackle the mounting challenges of expensive and inefficient drug development in an era of rising healthcare costs and aging populations. Their recommendations, published in the Journal of Clinical and Translational Science, chart a path toward more equitable, efficient, and inclusive clinical trials that better serve diverse communities.
Two women stand together in front of a tree.

All in the Family

Sisters Rebecca Kirkland and Mary Trent Jones are no strangers to volunteering, spending decades serving on boards, with Rebecca on the Duke University Board of Trustees and the D

Logo for 2024 ESC Congress

DCRI Shares Late-Breaking Results, Expert Insights at ESC Congress

Faculty members and fellows of the Duke Clinical Research Institute (DCRI) shared their expertise during the European Society of Cardiology Congress (ESC) in London, Aug. 30-Sept. 2. Late-breaking trial results presented by DCRI faculty at the meeting offered new insights into drug and device efficacy and capabilities.
Allyx Therapeutics logo over a faded image of a nurse holding the hands of a senior patient.

First Parkinson’s Disease Patient Treated with ALX-001 in Allyx Therapeutics, DCRI Study

Allyx Therapeutics has announced that the first patient has been dosed with its lead compound, ALX-001, in a new clinical study assessing safety, pharmacokinetics and potential therapeutic response in patients with Parkinson’s disease. ALX-001 is a highly selective, first-in-class, synapse-targeted, disease-modifying oral therapy. Allyx Therapeutics is a clinical-stage biotechnology company working to deliver a novel approach to preserve and protect synapses for people living with neurodegenerative diseases.